soho2023
ELEVENTH ANNUAL MEETING

When treating myelodysplastic syndrome (MDS), how successful is Luspatercept?

Ersin Bozan MD1, Burcu Aslan Candir MD1, Samet Yaman MD1, Mehmet Sinan Dal1, Fevzi Altuntaş1
1Ankara Oncology Training and Research Hospital, Department of Hematology and Bone Marrow Transplantation Center, University of Health Sciences, Ankara, Turkey.

INTRODUCTION

MDS is a hematological disease with its complications and improves quality of life. Luspatercept has a positive effect on both hematological parameters and quality of life, in some MDS patients.

AIM

In this abstract, we will present a patient with MDS diagnosed who has benefit from luspatarcept treatment.

METHOD

76-year-old patient, tested for anemia, high creatin, and splenomegaly, was last diagnosed with MDS low risk. Ring sideroblasts observed in the pathology of the patient with low erythropoetin level and the diagnosis of MDS-ring sideroblast was confirmed with the pathologist.
The patient with anemia and leukopenia received erythropoetine treatment, but there is no longer any response. The patient's GFR level was measured at 50% in the case of renal failure brought on by anemia. The patient received 1mg/kg/kg of luspatarcept over the course of 21 days. During the follow-up period, the patient received a total of 12 doses of luspatarcept.

RESULTS

The patient's creatine values completely returned to normal.
Erythrocyte suspension is not required. The frequency of infections decreased, and the leucocyte count increased to the normal reference range. The patient's quality of life significantly improved, while the hemogram and biochemistry values remained normal.

CONCLUSIONS

Luspatarcept provides significant improvement on hematopoesis, especially in low risk and ring sideroblastic variant MDS patients. In this way, patients are also protected from end organ damage caused by anemia. Especially in this patient group, it is critical to start luspatarcept before chronic organ damage.

REFERENCES

1-Fenaux P, Platzbecker U, Mufti GJ, et al. Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes. N Engl J Med. 2020 Jan 9;382(2):140-51.

2-Tinsley-Vance SM, Davis M, Ajayi O. Role of Luspatercept in the Management of Lower-Risk Myelodysplastic Syndromes. J Adv Pract Oncol. 2023 Jan;14(1):82-7.

ACKNOWLEDGEMENTS

Authors would like to thank all members of the study team, the patient and his families.

CONTACT INFORMATION

ersinbozan87@gmail.com
+90 507 037 50 43